Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12450518 | 0.74 | TRPV1 (0.40) | PTGS1PTGS2TRPV1TRPV4 | |
| SCHEMBL26441211 | 0.73 | ATM (0.38) | — | |
| SCHEMBL29876100 | 0.73 | WNT3A (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL30492966 | 0.72 | OGA (0.34) | OGADYRK1AALDH1A1CYP1A2 | |
| SCHEMBL30492969 | 0.72 | OGA (0.34) | OGADYRK1AALDH1A1CYP1A2 | |
| SCHEMBL23066271 | 0.72 | OGA (0.34) | OGADYRK1AALDH1A1CYP1A2 | |
| SCHEMBL24517470 | 0.72 | DYRK1A (0.42) | OGADYRK1AALDH1A1CYP1A2 | |
| SCHEMBL15435738 | 0.72 | OGA (0.39) | OGADYRK1AALDH1A1CYP1A2 | |
| SCHEMBL15075058 | 0.72 | TRPV1 (0.39) | HTR2AHTR2CHTR2BTRPV1 | |
| SCHEMBL12446824 | 0.71 | HTR2A (0.36) | HTR2AHTR2CHTR2BTRPV4NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320202-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2025-10-16 | — | — | US | disclosed |
| EP-4556473-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024027370-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2024-02-08 | — | — | WO | disclosed |
| WO-2024012308-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320202-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | PRMT5, PRMT1, PRMT8 | PTGS1 2347/4885PTGS2 3554/4885HTR2A 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.